New Cancer Liquid Biopsy Tool Developed

Cancer is one of the leading causes of death worldwide, and has been found to have a significantly higher rate of survival when diagnosed at early stages, before metastasis. During metastasis, a secondary growth is initiated by circulating tumor cells (CTCs) that shed from the primary tumor into the bloodstream to spread the cancer. A team of engineering researchers from NYU Abu Dhabi, led by NYUAD Assistant Professor of Mechanical and Biomedical Engineering Mohammad A. Qasaimeh, has developed a microfluidic platform that is compatible with cutting-edge procedures of atomic force microscopy (AFM).

The developed platform is used to capture CTCs from blood samples of prostate cancer patients, followed by AFM mechanical characterizations of CTCs, at the nanoscale, in search for new metastatic mechano-biomarkers.

While the general lifecycle of CTCs is somewhat recognized, the lifespan and interactions of CTCs while circulating in the bloodstream is still unknown. CTCs are very rare and hard to isolate from the background of billions of healthy blood cells, and thus their biological and mechanical phenotypes are still to be explored.

In their paper, the researchers presented the microfluidic technology they developed to separate CTCs from blood samples for further analysis. The CTCs were isolated from other blood cells by noting the differences in their affinity to different monoclonal antibodies. The developed tool is a combined microfluidic-AFM platform, where AFM analyses can be followed to investigate the elasticity and adhesive properties of the captured CTCs cancer cells.

CTCs represent a biomarker for the detection, diagnosis, and prognosis of cancer. As CTCs spread through the bloodstream, using their discovered characteristics, they can be removed through a liquid biopsy procedure. Isolated CTCs can be potentially used for drug testing and molecular profiling for precision cancer therapies. Far less invasive than a traditional tissue biopsy, liquid biopsy procedures have the potential to replace traditional tissue biopsies in the near future, and be performed in local clinics or pharmacies.

“With slight customizations, the platform can also be adapted to other types of cancers including breast and lung,” said the first author of the study and the Research Scientist of Engineering at NYUAD, Muhammedin Deliorman.

The authors hope that using the developed tool, nanomechanical properties of captured CTCs could help in the future to identify aggressive cancer CTCs phenotypes for developing more effective therapies.

Reference

Deliorman et al. (2020) AFM-compatible microfluidic platform for affinity-based capture and nanomechanical characterization of circulating tumor cells. Microsystems & Nanoengineering. DOI: https://doi.org/10.1038/s41378-020-0131-9

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.